ePPS-2202 is a study designed to evaluate the benefits of a dematerialised personalised care plan (PCP) compared to standard information/PCP for patients with advanced sarcomas receiving systemic treatment.
Participants will be randomised to an experimental group or a control group. Patients in the experimental group will receive the dematerialised PCP in addition to the standard PCP while patients in the control group will receive the standard PCP alone.
All patients will be followed until the end of second-line treatment, the start of a new line of treatment, or until the 24-month follow-up.
Sarcomas of soft tissues or viscera ;
Inoperable metastatic or locally advanced disease ;
Indication for systemic treatment with pazopanib, trabectedine, eribulin, ifosfamide or dacarbazine monotherapy ;
Patient covered by French social security ;
Prior inclusion in ePPS trial for a prior systemic treatment ;
Poor understanding of French ;
Difficulty accessing a computer ;
Pregnant or nursing woman ;
Centre Oscar Lambret
Lead sponsor
Canceropôle Nord Ouest
Collaborator